PMID- 38022621
OWN - NLM
STAT- MEDLINE
DCOM- 20231201
LR  - 20240325
IS  - 1664-3224 (Electronic)
IS  - 1664-3224 (Linking)
VI  - 14
DP  - 2023
TI  - Histological transformation into SCLC: An important resistance mechanism of NSCLC 
      upon immunotherapy.
PG  - 1275957
LID - 10.3389/fimmu.2023.1275957 [doi]
LID - 1275957
AB  - The phenomenon of histological transformation has been widely reported in 
      advanced non-small cell lung cancer (NSCLC) with EGFR mutations following the 
      failure of EGFR-TKI treatment. Recent evidence suggests that similar histological 
      changes can also occur in advanced NSCLC without driver gene mutations after 
      developing resistance to immunotherapy. In this review, it was found that 66.7% 
      of cases with immunotherapy-induced histological transformation were classified 
      as lung squamous cell carcinoma (LSCC), while histological conversion into lung 
      adenocarcinoma (LUAD) without EGFR or ALK gene mutations has rarely been 
      reported. There have been sporadic reports on the occurrence of mutual 
      transformation between LUAD and LSCC. The histological conversion from NSCLC into 
      small cell lung cancer (SCLC) appears to be significantly underestimated, likely 
      due to the infrequency of re-biopsy following the development of immunotherapy 
      resistance. Several studies have reported a close association between the 
      transformation and mutations at TP53 and the RB1 splice site, as well as the loss 
      of an FBXW7 mutation. However, the exact mechanisms underlying this conversion 
      remain unclear. Currently, there is a lack of guidelines for the management of 
      transformed SCLC from NSCLC following immunotherapy, with chemotherapy being the 
      most commonly employed treatment approach.
CI  - Copyright (c) 2023 Zeng, Ding, Ding and Wang.
FAU - Zeng, Jiao
AU  - Zeng J
AD  - Department of Hematology & Oncology, Jiujiang University Affiliated Hospital, 
      Jiujiang, Jiangxi, China.
AD  - Graduate Department, Gannan Medical University, Ganzhou, Jiangxi, China.
FAU - Ding, Xinjing
AU  - Ding X
AD  - Department of Oncology, First Affiliated Hospital of Nanchang University, 
      Nanchang, Jiangxi, China.
FAU - Ding, Jianghua
AU  - Ding J
AD  - Department of Hematology & Oncology, Jiujiang University Affiliated Hospital, 
      Jiujiang, Jiangxi, China.
FAU - Wang, Xin
AU  - Wang X
AD  - Department of Social Medicine and Public Health, School of Basic Medicine, 
      Jiujiang University, Jiujiang, Jiangxi, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20231030
PL  - Switzerland
TA  - Front Immunol
JT  - Frontiers in immunology
JID - 101560960
RN  - EC 2.7.10.1 (ErbB Receptors)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Non-Small-Cell Lung/therapy/drug therapy
MH  - *Small Cell Lung Carcinoma/therapy/drug therapy
MH  - *Lung Neoplasms/drug therapy/genetics
MH  - ErbB Receptors/genetics
MH  - *Adenocarcinoma of Lung/genetics
MH  - Immunotherapy
PMC - PMC10646212
OTO - NOTNLM
OT  - histological transformation
OT  - immunotherapy
OT  - non-small cell lung cancer
OT  - resistance
OT  - small cell lung cancer
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/11/29 18:42
MHDA- 2023/12/01 06:43
PMCR- 2023/01/01
CRDT- 2023/11/29 15:28
PHST- 2023/08/10 00:00 [received]
PHST- 2023/10/16 00:00 [accepted]
PHST- 2023/12/01 06:43 [medline]
PHST- 2023/11/29 18:42 [pubmed]
PHST- 2023/11/29 15:28 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fimmu.2023.1275957 [doi]
PST - epublish
SO  - Front Immunol. 2023 Oct 30;14:1275957. doi: 10.3389/fimmu.2023.1275957. 
      eCollection 2023.